Development and Validation of a Diagnostic Prediction Rule for Osteopenia

Thammabhorn Janwittayanuchit[1]

Naritsaret Kaewboonlert[2,*]

Pornthep Tangkanjanavelukul[2]

Kitirat Phattaramarut[2]

Pattama Thongdee[2]

1 Suranaree University of Technology Hospital, Nakhon Ratchasima 30000, Thailand

2 Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand

* Corresponding author: School of Surgery, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand. Tel: +66 4422 3956, E-mail: naritcvt@gmail.com

Abstract

Objectives

To triage patients with a high likelihood of osteopenia before referring them for a standard bone mass density test for diagnosis.

Introduction

Osteopenia defined by low bone mineral density, is a precursor for osteoporosis and is primarily associated with aging-linked natural bone loss in adulthood. The model and findings can be used to adopt an inclusive screening and swift treatment model that can work in most settings where resources are limited.

Methods

We developed a diagnostic prediction rule based on clinical characteristics. A retrospective cohort of 798 patients who were going to be diagnosed with osteopenia or osteoporosis, within January-September 2022. The multivariable logistic regression to assess potential predictors. The logistic coefficients were transformed as a risk-based scoring system. The internally validation was performed using a bootstrapping procedure.

Results

The model initially included seven predictors: sex, age, height, weight, body mass index, diabetes mellitus, and estimated glomerular filtration rate. However, after using backward elimination for model reduction, only three predictors—sex, age, and weight—were retained in the final model. The discrimination performance was assessed with the area under the receiver operating characteristic curve (AuROC); it was 0.779 (95%CI 0.74-0.82), and the calibration plot showed

good calibration. For internal validation, bootstrap resampling was utilized, yielding an AuROC of 0.768 (95% CI 0.73-0.81), indicating robust performance of the model.

Conclusions

This study developed and internally validated the Osteopenia Simple Scoring System. This clinical risk score could be one of the important tools for diagnosing osteopenia and allocating resources in resource-limited settings.

Keywords

Osteopenia, Osteoporosis, Risk prediction, Diagnostic prediction rule, Clinical prediction

Introduction

Osteopenia is a decrease in bone mineral density (BMD) below normal values for their ages, is the initial stage of bone loss, which may progress to a more severe condition i.e. osteoporosis. However, that doesn't always lead to osteoporosis depending on many factors. The primary cause of osteopenia is the natural bone loss that occurs gradually during adulthood. Secondary causes supposed to accelerate bone loss include lifestyle factors[1] such as smoking, certain underlying diseases, steroid usage, early menopausal woman, rheumatoid arthritis, and some medications as well. Osteopenia is often a precursor to osteoporosis, which are now diagnosed by measuring bone mineral density using dual energy X-ray absorptiometry bone scans.[2] The osteopenia, as defined by the World Health Organization (WHO) is a t-score between -1 to -2.5, while values less than -2.5 are diagnostic for osteoporosis.[3, 4] Osteopenia

is not considered a disease while osteoporosis is. In the other hand, osteopenia is considered a marker for risk of fractures.[5]

The potential predictors of bone mass density in patients with fractures treated in hospitals were found that factors such as age, sex, smoking, history of adult wrist fractures, spinal deformities[6, 7], history of adult hip fractures, and osteoarthritis of the spine[8] significantly differed statistically between groups with normal bone mass density and those with bone mass density below -1 standard deviation. Low body mass index, low vitamin D level[9] and diabetes[10, 11], chronic kidney disease[12] are also associated with osteoporosis.

There has been increasing attention to the clinical predictive models of diagnostic screening models for the prediction of fracture risk in patients diagnosed with osteoporosis.[13-16] Clinical predictive models are commonly used in clinics for the purpose of disease diagnosis, outcome prediction, and evaluation of the clinical response.[17, 18] We used multivariable logistic regression to develop predictive models for possible use in the facilitation of early treatment and screening for osteopenia.

In countries with limited resources, access to a test for bone mass density would be far-fetched. This research aims to help triage patients at high risk of having osteopenia before they are referred for a standard BMD test for diagnosis. This work could be extended to programs aimed to osteopenia or osteoporosis screening in the community.

Methods

Study design and setting

This diagnostic prediction research, utilizing a retrospective cohort design, was conducted at Suranaree University of Technology Hospital in Nakhon Ratchasima, located in the lower northeastern region of Thailand. Our university hospital conducts more than 2,000 bone mass density tests annually.

This study gathered demographic and laboratory data, including age, weight, height, body mass index, smoking status, early menopause, rheumatoid arthritis, diabetes mellitus, chronic kidney disease, serum creatinine, and estimated glomerular filtration rate levels from the electronic medical records of Suranaree University Technology Hospital. The data collection period spanned from January to September 2022. BMD was used in the analysis. Participants previously diagnosed with osteopenia or osteoporosis were excluded from the study.

Confirmation of cases

All patients included in this study underwent a BMD test on a single machine at the hospital's checkup center. In this study, osteopenia is defined as a T-score of less than -1, and osteoporosis is defined as a T-score of less than -2.5.

Statistical analysis and sample size calculations

Continuous variables were assessed for normality and presented as means and standard deviations if normally distributed, or medians and interquartile ranges if not. Mean differences of the variables between the two groups were compared by using an independent t-test, or rank-sum test based on the distribution of the data. Categorical data were expressed as frequencies and percentages of the total in each group and compared between groups using either the exact probability test or chi-square test where applicable. We assessed diagnostic performance and

113 potential prediction by univariable logistic regression, using crude odds ratios (OR) and their
114 corresponding area under the receiver operating characteristic curves (AuROC). Statistically
115 significant two-sided p-values less than 0.05 were considered in applicable cases. All analyses
116 were done using Stata statistical software version 17. In the development of clinical prediction
117 rules based on methods described by Riley et al.[19], it was estimated that the minimum sample
118 size for a multivariable prediction model with a binary outcome was required. This was estimated
119 from a model c-statistic of 0.8, six candidate predictors, and an assumed prevalence of
120 osteopenia from a preliminary study, standing at 46%, to get the minimum sample size of 382
121 cases with 176 events.

122

123 Model development and validation

124 All potential predictor variables necessary for diagnostic prediction of osteopenia in our
125 routine practice were extracted from the hospital's electronic medical records. These included
126 age, sex, height, weight, smoking status, serum creatinine levels, diabetes mellitus (with or
127 without insulin use), hypertension, early menopause, chronic kidney disease, steroid use, and
128 rheumatoid arthritis.

129 We identified potential predictors based on prior knowledge; about the biological process,
130 a review of the literature, and available prediction models. Subsequently, the exploratory analysis
131 of significant predictors was done using a univariable logistic regression. We assessed the
132 significance of the predictors through the diagnostic odds ratio and the corresponding p-value.
133 Additionally, we assessed the area under the receiver operating characteristic curve (AuROC) for
134 each univariable logistic model. Any predictor variable showing an odds ratio >1.00, significant p-
135 value of <0.05, and higher AuROC than others was included in the model. Continuous potential
136 variables were categorized into ordinal following the preceding model and review of literature.

Therefore, in this respect, understanding the nature of the relationship between the dependent variable and the outcome to determines the cut-off point.

The model to be used for the study is derived from the multivariable logistic regression with a binary outcome. The factors that not contributing to the outcome were removed using the backward elimination method. A total of four predictors got pruned from the model: height, body mass index, diabetes mellitus, and estimated glomerular filtration rate. Diagnostic performance of the developed model was assessed using the reduced multivariable model by means of calibration and discrimination. Calibration was assessed by the Hosmer-Lemeshow goodness-of-fit test, and a plot was applied to show both the model-estimated disease probabilities and observed disease data. The discriminative ability of the model was graphically tested through a distributional plot. It was reported with the area under the curve of the receiver operating characteristic. The internal validation was conducted using the bootstrapping procedure of 1000 replications.

Simplified score derivation

Each predictor in the multivariable model was assigned a specific score based on the logistic regression coefficients. The coefficient of each predictor was divided by the smallest coefficient and then rounded up to the nearest whole number. Utilizing a population-analogue approach, the positive predictive value (PPV) was calculated to demonstrate the predictive performance. Calibration and discrimination measurements were also conducted using the score-based multivariable logistic model.

Ethical considerations

This research was conducted based on ethical standards of clinical research. According to the Helsinki Declaration and began its activity only after it received approval and permission from the Institutional Review Board of Suranaree University of Technology regarding the review of the research protocol. Retrospective data were extracted through data record forms. The patients were treated by the routine hospital staff and were not affected by any research protocols, the informed consent was waived. The study adhered to the reporting guidelines outlined in the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement. The study protocol received approval from the Institutional Review Board of Suranaree University of Technology, with approval number COA No.32/2567.

Results

Participants

A total of 798 participants were evaluated for osteopenia at the Suranaree University of Technology check-up center from January to September 2022. After excluding 242 patients previously diagnosed with osteopenia or osteoporosis, the remaining 556 patients were divided into two groups: 230 in the osteopenia group and 326 in the non-osteopenia group. The prevalence of osteopenia and osteoporosis was 41.4% and 5.4%, respectively. Of these, 198 patients in the osteopenia group and 188 in the non-osteopenia group were female. The mean age for the osteopenia group was 65.07±10.34 years, compared to 59.03±9.14 years for the non-osteopenia group. The average weight was 57.40±9.58 kg for osteopenia cases and 57.40±12.71 kg for non-osteopenia cases. Average heights were 155.22±7.50 cm for the osteopenia group and 160.53±8.00 cm for the non-osteopenia group. The mean BMI was 24.68±14.44 kg/m^2 for osteopenia cases and 25.64±4.02 kg/m^2 for non-osteopenia cases (Table 1). There were

183 significant differences in groups in terms of female gender, age, weight, height, BMI, and current
184 underlying diseases, including diabetes mellitus, as well as in laboratory factors such as estimated
185 glomerular filtration rate (eGFR) ($p < 0.001$). There were no significant differences in the serum
186 creatinine, early menopause, rheumatoid arthritis, and smoking status.

187

188 Model development and internal validation

189 The following continuous variables were converted to ordinal variables: eGFR, body mass
190 index, weight, age, and height. The cut points were determined based on information gathered
191 from the literature and prior models. The model was developed using multivariable logistic
192 regression, which demonstrated the relevant characteristics included in the regression for
193 predicting osteopenia were female gender, age, height, weight, BMI, diabetes mellitus, and eGFR.
194 These factors remained significant in the multivariable logistic regression analysis and were
195 integrated into the full risk prediction model (Table 2).

196 The reduced model employed a backward elimination strategy. Multivariable logistic
197 regression indicated that female gender, age, and weight, which were included in the final model,
198 were found to be statistically significant. The scoring ranged from 1 to a maximum of 5 points,
199 accumulating to a total of 13 points, summing up to 133. Ages over 70 years were assigned the
200 highest scores (Table 3).

201 The calibration plot of the estimated risk of osteopenia compared to the actual risk showed
202 acceptable calibration, with observed probabilities closely matching the expected probabilities
203 and exhibiting minimum variation from the ideal (Figure 2). The Hosmer-Lemeshow goodness-of-
204 fit statistic yielded a non-significant result for the outcome ($p = 0.614$), suggesting that the
205 statistical fitness of the model was satisfactory, given that a p-value larger than 0.1 was regarded

206 indicative of a good fit. Area under the receiver operating characteristic curve (AuROC) was
207 0.7792 (95% CI 0.74-0.82), showing a good performance in model discrimation (Figure 3).

208 The process of internal validation was conducted by utilizing a bootstrap resampling
209 technique with 1000 repeats. Following the adjustment for optimism in discrimination, the
210 bootstrap analysis produced an area under the receiver operating characteristic curve (AuROC)
211 of 0.768 (95% CI 0.73-0.81), indicates a good ability and a significant level of agreement between
212 the estimated and observed probabilities of risk (Supplementary material).

213

214 Simple score cut point identification

215 A very high sensitivity of 94.8% (95% CI 91.1-97.3) was observed at a cut point of ≥4,
216 while the specificity was 28.5% (95% CI 23.7-33.8). At a score of ≥10, the specificity was high at
217 91.7% (95% CI 88.2-94.5), but the sensitivity was lower at 44.3% (95% CI 37.8-51.0). The best
218 cut point was determined by achieving a balance between sensitivity and specificity. For a score
219 of 6 or above, the sensitivity was 82.2% (95% CI 76.6-86.9), and the specificity was 55.2% (95%
220 CI 49.6-60.7), with a likelihood ratio of positive result of 1.83 (95% CI 1.60-2.10). The positive
221 predictive value was 56.4% (95% CI 50.9-61.8), whereas the negative predictive value was 81.4%
222 (95% CI 75.7-86.3) (Table 4).

223

224 Clinical utility

225 In the context of triaging patients for osteopenia, the newly developed diagnostic
226 prediction rule was applied. 32.37% (180 patients out of 556) were true negatives, this model can
227 reduce the unnecessary BMD tests. Among the 211 patients who scored negatively (simple score
228 below 6), 41 patients (18.55%) were false negatives for osteopenia, and only 2 patients (0.36%

229 of all patients) were diagnosed with osteoporosis. On the other hand, among those with a positive
230 score test (simple score above 6), 146 patients had normal BMD and were recommended for
231 follow-up, while 189 patients were confirmed to have osteopenia and received medical treatment
232 according to the treatment guidelines.

233

234 Discussion

235 Despite the limitations, the current study managed to establish a diagnostic rule for
236 predicting patients with osteopenia, which could strengthen an early diagnosis and the treatment
237 of patients in osteopenia. This finding is highly relevant because our hospital faces a significant
238 burden of bone density testing and a high prevalence of osteopenia. Moreover, the application of
239 a predictive diagnosis logistic regression model, as conducted in the current study, also supports
240 the efforts of other studies to implement more predictive analytics in clinical settings[20].

241 Our results emphasize the importance of a multi-factor approach in novel predictive model
242 formulation. Specifically, our model uses the same age, sex, and weight as the known risk factors,
243 established to predict osteopenia and osteoporosis, proven to be significant in other studies.[21]
244 Similarly, the use of backward elimination for the purpose of precise identification of the factors
245 allowed reducing the insignificant height and BMI from the model, as these variables have
246 negligible impact on the model's predictability of outcomes in our patients.[22]

247 The calibration and discrimination results of our model are satisfactory and being
248 confirmed. The results of the Hosmer-Lemeshow test and AuROC testify to the model's effective
249 prediction of true osteopenia cases. This is confirmed by the literature on the appropriateness of
250 calculating these metrics to check how well a diagnostic tool performs in clinical epidemiology
251 and diagnostics.[23]

Furthermore, the use of this model demonstrated its significant clinical use. The prioritization of resources based on a simple score, which identifies high and low-risk patients, may also lower the risk of untreated osteopenia transitioning to osteoporosis and adhere to WHO, who suggests that more tests should be conducted on populations at higher risks.[24, 25]

Although the FRAX score is currently used in predicting the 10-year probability of hip fracture[26, 27], a study by Teeratakulpisarn et al[28]. reports that even though there is concordance between the 10-year probability of hip fractures for FRAX scores with and without BMD, this concordance declines in elderly and osteoporotic participants, and in those with FRAX scores without BMD. Therefore, to achieve higher accuracy, it is advisable to undergo BMD testing.

In 2001, Koh LK et al.[29] designed a simple tool to categorize postmenopausal Asian women (OSTA score). They utilized a questionnaire to identify those in the cohort with osteoporosis, defined as BMD T-scores ≤ -2.5 and use multivariable logistic regression analysis. The tool had a good performance with an area under the ROC curve of 0.79. Subsequently, it showed sensitivity of 91%, specificity of 45%, among others.[29] Additionally, upon a validation in Thai population, OSTA score presented sensitivity of 51.7% and specificity of 77.4% with a false negative rate of ~20%.[30-33] The OSTA risk classification system showed that high and medium-risk patients were significantly more likely to sustain injuries in falls and have different femoral bone fractures patterns compared to low-risk patients. Machine learning models particularly artificial neural networks offer another opportunity to predict low BMD. Comparison of both ANN models to logistic regression models to predict low BMD had no significantly different in performance for either the femoral neck or lumbar spine.[34] Although the OSTA score performs well within the Thai population and particularly among postmenopausal women, however, it can be limited use to the general population.

Our model's stability and reliability were internal validation via bootstrapping, process accounting for the potential optimism that can compromise prediction models developed in narrow or specific populations. All of these methods make our research more reliable and can be used to apply to similar settings with limited health care resources.

The study also has its limitations. In particular, the specificity of the model at some cut points was insufficient for real-life applications, resulting in overdiagnosis and overtreatment. This compromise between sensitivity and specificity is common in the development of diagnostic instruments, and it needs to be adjusted depending on the costs and risks of the disease. For future research, it is possible not only to include new, more prognostic factors but also to progress statistical instruments, such as machine learning. Further external validation is also required before adopting this model in other settings.

Conclusion

The development of a diagnostic prediction rule for osteopenia in a resource-limited context is a major progress in the field of bone health management. This instrument is likely to enhance patient prognosis and maximize the use of available healthcare resources by detecting and offering timely therapeutic treatment to those at risk.

Acknowledgement

This paper was supported by Suranaree University of Technology.

Funding

None

Conflict of interest

None

Author contribution statement

NK and TJ contributed to all parts of the research.PT, KP, and PT focused on discussing, reviewing, and editing the manuscript.

Figure legends

Figure 1: Study flow.

Figure 2: Calibration plot for model predicted risk for osteopenia versus actual risk.

Figure 3: Discrimination performance of the newly developed model, using clinical characteristics to classify patients with normal and low bone mass density.

Figure 4: Clinical utility.

Tables

315 **Table 1:** Baseline patient characteristics, underlying diseases, and laboratory investigations of

316 the derivation cohort, along with a comparison of osteopenia cases and normal bone mineral

317 density tests (n = 556).

Patient characteristics	Osteopenia cases (n = 230)		Non-osteopenia cases (n = 326)		Univariable OR (95%CI)	p-value	AuROC
	n	(%)	n	(%)			
Female gender	198	(86.09)	188	(57.67)	4.54 (2.94-7.00)	< 0.001	0.64 (0.61-0.68)
Age, years (mean ± SD)	65.07	± 10.34	59.03	± 9.14	1.07 (1.05-1.09)	< 0.001	0.68 (0.64-0.73)
Weight, kg (mean ± SD)	57.40	± 9.58	66.30	± 12.71	0.93 (0.91-0.95)	< 0.001	0.29 (0.25-0.34)
Height, cm (mean ± SD)	155.22	± 7.50	160.53	± 8.03	0.92 (0.89-0.94)	< 0.001	0.32 (0.28-0.37)
BMI, km/m^2 (mean ± SD)	24.68	± 14.44	25.64	± 4.02	0.88 (0.84-0.93)	< 0.001	0.37 (0.33-0.42)
Current smoking	1	(0.43)	5	(1.54)	0.28 (0.03-2.40)	0.245	0.49 (0.49-0.50)
Early menopause	5	(2.17)	10	(3.09)	0.70 (0.24-2.07)	0.516	0.50 (0.48-0.51)
Rheumatoid arthritis	1	(0.43)	2	(0.62)	0.70 (0.06-7.80)	0.774	0.50 (0.49-0.51)
Diabetes mellitus	15	(6.52)	45	(13.89)	0.43 (0.23-0.80)	0.007	0.46 (0.44-0.49)
Creatinine, g/dL (mean ± SD)	0.87	± 0.72	0.87	± 0.37	1.01 (0.72-1.42)	0.967	0.42 (0.37-0.48)
eGFR, ml/min/1.73 m^2 (mean ± SD)	68.59	± 24.13	83.71	± 25.39	0.97 (0.97-0.98)	< 0.001	0.32 (0.28-0.37)
Chronic kidney disease	25	(10.92)	37	(11.46)	0.95 (0.55-1.62)	0.844	0.50 (0.47-0.52)

318 Abbreviations: eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval

319

320 **Table 2:** Full model multivariable logistic regression analysis.

Predictors	Full model		
	mOR	95% CI	P-value
Female	5.33	3.03 - 9.38	0.000
Age, year			
≤ 59	1		
60 – 69	3.59	2.25 - 5.74	< 0.001
≥ 70	6.91	3.62 - 13.20	< 0.001
Height, cm			
≥ 155	1		
< 155	0.97	0.57 - 1.64	0.903
Weight, kg			

≥ 70	1		
60 – 69	1.15	0.61 - 2.17	0.656
50 – 59	1.66	0.72 - 3.82	0.233
≤ 49	1.72	0.54 - 5.54	0.360
Body mass index, kg/m^2			
≥ 25.0	1		
23.0 – 24.9	1.19	0.64 - 2.22	0.577
18.5 – 22.9	1.71	0.79 - 3.69	0.169
< 18.5	3.94	0.87 - 17.90	0.076
Diabetes mellitus	0.35	0.17 - 0.71	0.004
Estimated GFR			
≥ 60	1		
30 – 59	0.84	0.45 - 1.54	0.565
15 – 29	1.89	0.22 - 16.05	0.558
≤ 14	1	Empty	
Model intercept	.062		

Abbreviation: mOR, multivariable odds ratio; BMI, body mass index; GFR, glomerular filtration rate

Table 3: Reduced model with logit coefficients.

Predictors	mOR	95% CI	P-value	β Coefficient	Score
Female	4.09	2.51 - 6.68	0.000	1.41	4
Age, year					
≤ 59	1				
60 – 69	3.29	2.13 - 5.08	0.000	1.19	3.5
≥ 70	5.52	3.21 - 9.50	0.000	1.71	5
Weight, kg					
≥ 70	1				
60 – 69	1.40	0.80 - 2.45	0.240	0.34	1
50 – 59	2.60	1.51 - 4.50	0.001	0.96	3
≤ 49	3.96	2.02 - 7.76	0.000	1.38	4

Model intercept	.065				

Abbreviation: mOR, multivariable odds ratio; BMI, body mass index

Table 4: Selection of score cut-off point with sensitivity, specificity, LHR+, PPV, NPV, and along with 95% confidence interval.

Score cut point	Sensitivity (%)	Specificity (%)	LHR+ (%)	PPV (%)	NPV (%)
≥ 4	94.8 (91.1-97.3)	28.5 (23.7-33.8)	1.33 (1.23-1.43)	48.3 (43.6-53.1)	88.6 (80.9-94.0)
≥ 6	82.2 (76.6-86.9)	55.2 (49.6-60.7)	1.83 (1.60-2.10)	56.4 (50.9-61.8)	81.4 (75.7-86.3)
≥ 10	44.3 (37.8-51.0)	91.7 (88.2-94.5)	5.35 (3.63-7.90)	79.1 (71.0-85.7)	70.0 (65.4-74.3)

Abbreviation: LHR+, likelihood ratio for positive test; PPV, positive predictive value; NPV, negative predictive value

References

1. Rychter AM, Ratajczak AE, Szymczak-Tomczak A, Michalak M, Eder P, Dobrowolska A, et al. Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with Inflammatory Bowel Disease. Nutrients. 2021;13(6). Epub 2021/06/03. doi: 10.3390/nu13061863. PubMed PMID: 34070791; PubMed Central PMCID: PMCPMC8227497.
2. Blake GM, Fogelman I. The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J. 2007;83(982):509-17. Epub 2007/08/07. doi: 10.1136/pgmj.2007.057505. PubMed PMID: 17675543; PubMed Central PMCID: PMCPMC2600106.
3. Sözen T, Özışık L, Başaran N. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46-56. Epub 2017/03/16. doi: 10.5152/eurjrheum.2016.048. PubMed PMID: 28293453; PubMed Central PMCID: PMCPMC5335887.

4. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16 Suppl 2:S3-7. Epub 2004/09/15. doi: 10.1007/s00198-004-1702-6. PubMed PMID: 15365697.
5. Tran T, Bliuc D, Pham HM, van Geel T, Adachi JD, Berger C, et al. A Risk Assessment Tool for Predicting Fragility Fractures and Mortality in the Elderly. J Bone Miner Res. 2020;35(10):1923-34. Epub 2020/05/28. doi: 10.1002/jbmr.4100. PubMed PMID: 32460361.
6. Rozental TD, Shah J, Chacko AT, Zurakowski D. Prevalence and predictors of osteoporosis risk in orthopaedic patients. Clin Orthop Relat Res. 2010;468(7):1765-72. Epub 2009/11/17. doi: 10.1007/s11999-009-1162-6. PubMed PMID: 19911243; PubMed Central PMCID: PMCPMC2881983.
7. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3-11. Epub 2006/02/02. doi: 10.1016/j.ajog.2005.08.047. PubMed PMID: 16448873.
8. Grams AE, Rehwald R, Bartsch A, Honold S, Freyschlag CF, Knoflach M, et al. Correlation between degenerative spine disease and bone marrow density: a retrospective investigation. BMC Med Imaging. 2016;16:17. Epub 2016/02/26. doi: 10.1186/s12880-016-0123-2. PubMed PMID: 26911278; PubMed Central PMCID: PMCPMC4765052.
9. Tang G, Feng L, Pei Y, Gu Z, Chen T, Feng Z. Low BMI, blood calcium and vitamin D, kyphosis time, and outdoor activity time are independent risk factors for osteoporosis in postmenopausal women. Front Endocrinol (Lausanne). 2023;14:1154927. Epub 2023/11/08. doi: 10.3389/fendo.2023.1154927. PubMed PMID: 37937050; PubMed Central PMCID: PMCPMC10627178.
10. Tang Y, Zhang L, Ye D, Zhao A, Liu Y, Zhang M. Causal relationship between Type 1 diabetes and osteoporosis and fracture occurrence: a two-sample Mendelian randomization analysis. Osteoporos Int. 2023;34(6):1111-7. Epub 2023/04/04. doi: 10.1007/s00198-023-06734-6. PubMed PMID: 37012460.
11. Ali D, Tencerova M, Figeac F, Kassem M, Jafari A. The pathophysiology of osteoporosis in obesity and type 2 diabetes in aging women and men: The mechanisms and roles of increased bone marrow adiposity. Front Endocrinol (Lausanne). 2022;13:981487. Epub 2022/10/04. doi: 10.3389/fendo.2022.981487. PubMed PMID: 36187112; PubMed Central PMCID: PMCPMC9520254.
12. Hampson G, Elder GJ, Cohen-Solal M, Abrahamsen B. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine. 2021;73(3):509-29. Epub 2021/05/12. doi: 10.1007/s12020-021-02735-9. PubMed PMID: 33974225; PubMed Central PMCID: PMCPMC8325650.
13. Tan J, Zhang Z, He Y, Xu X, Yang Y, Xu Q, et al. Development and validation of a risk prediction model for osteoporosis in elderly patients with type 2 diabetes mellitus: a retrospective and multicenter study. BMC Geriatrics. 2023;23(1):698. doi: 10.1186/s12877-023-04306-1.
14. Mauck KF, Cuddihy MT, Atkinson EJ, Melton LJ, 3rd. Use of clinical prediction rules in detecting osteoporosis in a population-based sample of postmenopausal women. Arch Intern Med. 2005;165(5):530-6. Epub 2005/03/16. doi: 10.1001/archinte.165.5.530. PubMed PMID: 15767529.
15. Leeyaphan J, Rojjananukulpong K, Intarasompun P, Peerakul Y. Development and Validation of a New Clinical Diagnostic Screening Model for Osteoporosis in Postmenopausal Women. J Bone Metab. 2023;30(2):179-88. Epub 2023/07/14. doi: 10.11005/jbm.2023.30.2.179. PubMed PMID: 37449350; PubMed Central PMCID: PMCPMC10346005.
16. Wang J, Kong C, Pan F, Lu S. Construction and Validation of a Nomogram Clinical Prediction Model for Predicting Osteoporosis in an Asymptomatic Elderly Population in Beijing. J Clin Med. 2023;12(4). Epub 2023/02/26. doi: 10.3390/jcm12041292. PubMed PMID: 36835828; PubMed Central PMCID: PMCPMC9967366.

17. Aibar-Almazán A, Voltes-Martínez A, Castellote-Caballero Y, Afanador-Restrepo DF, Carcelén-Fraile MDC, López-Ruiz E. Current Status of the Diagnosis and Management of Osteoporosis. Int J Mol Sci. 2022;23(16). Epub 2022/08/27. doi: 10.3390/ijms23169465. PubMed PMID: 36012730; PubMed Central PMCID: PMCPMC9408932.
18. Sun X, Chen Y, Gao Y, Zhang Z, Qin L, Song J, et al. Prediction Models for Osteoporotic Fractures Risk: A Systematic Review and Critical Appraisal. Aging Dis. 2022;13(4):1215-38. Epub 2022/07/21. doi: 10.14336/ad.2021.1206. PubMed PMID: 35855348; PubMed Central PMCID: PMCPMC9286920.
19. Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE, Jr., Moons KG, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019;38(7):1276-96. Epub 2018/10/26. doi: 10.1002/sim.7992. PubMed PMID: 30357870; PubMed Central PMCID: PMCPMC6519266.
20. Riley RD, Pate A, Dhiman P, Archer L, Martin GP, Collins GS. Clinical prediction models and the multiverse of madness. BMC Med. 2023;21(1):502. Epub 2023/12/19. doi: 10.1186/s12916-023-03212-y. PubMed PMID: 38110939; PubMed Central PMCID: PMCPMC10729337.
21. Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029-49. Epub 2018/11/23. doi: 10.2147/tcrm.S138000. PubMed PMID: 30464484; PubMed Central PMCID: PMCPMC6225907.
22. Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health. 2020;8(1):e000262. Epub 2020/03/10. doi: 10.1136/fmch-2019-000262. PubMed PMID: 32148735; PubMed Central PMCID: PMCPMC7032893.
23. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. Jama. 2017;318(14):1377-84. Epub 2017/10/20. doi: 10.1001/jama.2017.12126. PubMed PMID: 29049590.
24. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6):368-81. Epub 1994/11/01. doi: 10.1007/bf01622200. PubMed PMID: 7696835.
25. Rubin KH, Holmberg T, Rothmann MJ, Høiberg M, Barkmann R, Gram J, et al. The risk-stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-based study. Design and baseline characteristics. Calcif Tissue Int. 2015;96(2):167-79. Epub 2015/01/13. doi: 10.1007/s00223-014-9950-8. PubMed PMID: 25578146.
26. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12(12):989-95. Epub 2002/02/16. doi: 10.1007/s001980170006. PubMed PMID: 11846333.
27. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International Variations in Hip Fracture Probabilities: Implications for Risk Assessment. Journal of Bone and Mineral Research. 2002;17(7):1237-44. doi: https://doi.org/10.1359/jbmr.2002.17.7.1237.
28. Teeratakulpisarn N, Charoensri S, Theerakulpisut D, Pongchaiyakul C. FRAX score with and without bone mineral density: a comparison and factors affecting the discordance in osteoporosis treatment in Thais. Arch Osteoporos. 2021;16(1):44. Epub 2021/02/27. doi: 10.1007/s11657-021-00911-y. PubMed PMID: 33635451.
29. Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, et al. A simple tool to identify asian women at increased risk of osteoporosis. Osteoporos Int. 2001;12(8):699-705. Epub 2001/10/03. doi: 10.1007/s001980170070. PubMed PMID: 11580084.
30. Chaovisitsaree S, Namwongprom SN, Morakote N, Suntornlimsiri N, Piyamongkol W. Comparison of osteoporosis self assessment tool for Asian (OSTA) and standard assessment in

457 Menopause Clinic, Chiang Mai. J Med Assoc Thai. 2007;90(3):420-5. Epub 2007/04/13.
458 PubMed PMID: 17427514.
459 31. Geater S, Leelawattana R, Geater A. Validation of the OSTA index for discriminating
460 between high and low probability of femoral neck and lumbar spine osteoporosis among Thai
461 postmenopausal women. J Med Assoc Thai. 2004;87(11):1286-92. Epub 2005/04/14. PubMed
462 PMID: 15825701.
463 32. Chen CC, Rau CS, Wu SC, Kuo PJ, Chen YC, Hsieh HY, et al. Association of
464 Osteoporosis Self-Assessment Tool for Asians (OSTA) Score with Clinical Presentation and
465 Expenditure in Hospitalized Trauma Patients with Femoral Fractures. Int J Environ Res Public
466 Health. 2016;13(10). Epub 2016/10/14. doi: 10.3390/ijerph13100995. PubMed PMID:
467 27735874; PubMed Central PMCID: PMCPMC5086734.
468 33. Panichyawat N, Tanmahasamut P. Comparison of OSTA index and KKOS scoring
469 system for prediction of osteoporosis in postmenopausal women who attended Siriraj
470 Menopause Clinic. J Med Assoc Thai. 2012;95(11):1365-71. Epub 2012/12/21. PubMed PMID:
471 23252200.
472 34. Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, Piaseu N, Teerarungsikul K, Sirisriro
473 R, et al. Prediction of low bone mineral density in postmenopausal women by artificial neural
474 network model compared to logistic regression model. J Med Assoc Thai. 1997;80(8):508-15.
475 Epub 1997/08/01. PubMed PMID: 9277083.

476


Patients intended to be diagnosed with osteopenia in the Check-up center at Suranaree university of technology.
From January to September 2022
n = 798
Exclude (n = 242)
- Previous diagnosed osteopenia or osteoporosis
Patient clinical parameter was recorded.
Bone mineral density (BMD) test
(n = 556)
Osteopenia
(n = 230)
No osteopenia
(n = 326)

Figure 1


E:O = 1.000
CITL = 0.000
Slope = 1.000
AUC = 0.779
Observed
Expected
0
.2
.4
.6
.8
1
Reference
Groups
95% CIs

Figure 2


Sensitivity
0.00
0.25
0.50
0.75
1.00
1 - specificity
Area under ROC curve = 0.7792

Figure 3


Patients intended to be diagnosed with osteopenia.
(n = 556)
Diagnostic prediction model, Score cut point ≥ 6
Negative
Positive
Follow-up (n = 221)
False negative, n = 41 (18.55%)
Bone mineral density test (n = 335)
Negative
Positive
Follow-up (n = 146)
Treatment (n = 189)

Figure 4